Filing Flows › Sight Sciences (SGHT) › Q4 2025
Sight Sciences (SGHT) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 4, 2026
Sight Sciences (SGHT) reported revenue of $20.4M for the fourth quarter 2025 (Q4 2025), +7% from a year earlier and +2% from the quarter before. Operating margin was -18.0%, net loss $4.2M (20.4% of revenue).
Sight Sciences, Q4 2025: revenue $20.4M (+7% year over year), operating margin -18.0%, net loss $4.2M, operating cash flow −$1.8M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.4M | +2% | +7% |
| Operating profit | −$3.7M | — | — |
| Net earnings | −$4.2M | — | — |
| Operating cash flow | −$1.8M | — | — |
What changed
Revenue was $20.4M in Q4 2025, up 7% year over year and up 2% from the previous quarter. Surgical Glaucoma was the largest line at 96% of revenue.
Gross margin was 87.3%, up 0.4 points from a year earlier. Operating costs exceeded revenue by $3.7M, an operating margin of -18.0%. Operating expenses fell 25% while revenue rose 7%. The quarter ended with a net loss of $4.2M, narrower than the previous quarter's $8.2M loss.
Operating cash flow was −$1.8M. Non-cash charges added back $108K of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items used $322K. Capital expenditures of −$156K exceeded it, leaving free cash flow of −$1.7M.
Questions
What was Sight Sciences' revenue in the fourth quarter 2025?
Sight Sciences (SGHT) reported revenue of $20.4M for the fourth quarter 2025 (Q4 2025), +7% from a year earlier and +2% from the quarter before.
Was Sight Sciences profitable in the fourth quarter 2025?
Operating loss was $3.7M (-18.0% of revenue) and net loss $4.2M.
Source: Sight Sciences 10-K on SEC EDGAR.